Capstone Investment Advisors’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.44M | Buy |
38,900
+18,200
| +88% | +$1.46M | ﹤0.01% | 593 |
|
|
2025
Q4 | $1.97M | Sell |
20,700
-25,100
| -55% | -$2.46M | ﹤0.01% | 632 |
|
|
2025
Q3 | $4.47M | Buy |
45,800
+27,800
| +154% | +$2.88M | 0.01% | 501 |
|
|
2025
Q2 | $1.93M | Sell |
18,000
-9,500
| -35% | -$961K | ﹤0.01% | 656 |
|
|
2025
Q1 | $2.77M | Sell |
27,500
-40,900
| -60% | -$4.12M | 0.01% | 600 |
|
|
2024
Q4 | $6.11M | Buy |
68,400
+4,500
| +7% | +$396K | 0.01% | 477 |
|
|
2024
Q3 | $5.35M | Sell |
63,900
-8,900
| -12% | -$702K | 0.02% | 434 |
|
|
2024
Q2 | $5.61M | Buy |
72,800
+400
| +0.6% | +$29.3K | 0.02% | 424 |
|
|
2024
Q1 | $4.96M | Sell |
72,400
-28,800
| -28% | -$1.85M | 0.02% | 444 |
|
|
2023
Q4 | $5.85M | Buy |
101,200
+55,400
| +121% | +$2.96M | 0.02% | 482 |
|
|
2023
Q3 | $2.42M | Buy |
45,800
+4,200
| +10% | +$220K | 0.01% | 660 |
|
|
2023
Q2 | $2.25M | Buy |
41,600
+17,900
| +76% | +$935K | 0.01% | 607 |
|
|
2023
Q1 | $1.19M | Sell |
23,700
-700
| -3% | -$33K | 0.01% | 742 |
|
|
2022
Q4 | $1.13M | Buy |
24,400
+1,500
| +7% | +$65K | 0.01% | 888 |
|
|
2022
Q3 | $887K | Buy |
22,900
+3,100
| +16% | +$124K | 0.01% | 1080 |
|
|
2022
Q2 | $738K | Sell |
19,800
-98,800
| -83% | -$4.02M | ﹤0.01% | 1117 |
|
|
2022
Q1 | $5.25M | Sell |
118,600
-102,600
| -46% | -$4.45M | 0.01% | 688 |
|
|
2021
Q4 | $9.4M | Buy |
221,200
+45,800
| +26% | +$1.92M | 0.02% | 631 |
|
|
2021
Q3 | $7.61M | Buy |
175,400
+2,800
| +2% | +$124K | 0.02% | 706 |
|
|
2021
Q2 | $7.38M | Sell |
172,600
-60,700
| -26% | -$2.55M | 0.02% | 618 |
|
|
2021
Q1 | $9.02M | Buy |
233,300
+138,400
| +146% | +$5.24M | 0.03% | 489 |
|
|
2020
Q4 | $3.41M | Buy |
94,900
+20,600
| +28% | +$742K | 0.01% | 724 |
|
|
2020
Q3 | $2.84M | Buy |
74,300
+9,000
| +14% | +$347K | 0.01% | 692 |
|
|
2020
Q2 | $2.29M | Buy |
65,300
+7,300
| +13% | +$263K | 0.02% | 670 |
|
|
2020
Q1 | $1.89M | Sell |
58,000
-78,000
| -57% | -$3.05M | 0.03% | 539 |
|
|
2019
Q4 | $6.15M | Buy |
136,000
+13,100
| +11% | +$548K | 0.03% | 483 |
|
|
2019
Q3 | $5M | Buy |
122,900
+26,300
| +27% | +$1.11M | 0.03% | 437 |
|
|
2019
Q2 | $4.15M | Buy |
96,600
+38,600
| +67% | +$1.48M | 0.03% | 513 |
|
|
2019
Q1 | $2.23M | Buy |
58,000
+21,200
| +58% | +$810K | 0.02% | 565 |
|
|
2018
Q4 | $1.3M | Buy |
36,800
+2,900
| +9% | +$105K | 0.02% | 544 |
|
|
2018
Q3 | $1.3M | Buy |
+33,900
| New | +$1.18M | 0.01% | 533 |
|
|
2014
Q1 | – | Sell |
-50,000
| Closed | -$601K | – | 392 |
|
|
2013
Q4 | $601K | Hold |
50,000
| – | – | 0.01% | 425 |
|
|
2013
Q3 | $587K | Buy |
+50,000
| New | +$541K | 0.01% | 455 |
|
Other funds holding BSX
VCM
VPM
Capstone Investment Advisors's BSX Position: Q1 2026 in Review
Capstone Investment Advisors increased its Boston Scientific (BSX) stake by 647% in Q1 2026, buying an estimated $5.42M and bringing the position to 78,247 shares worth $4.91M. The position accounts for 0.01% of the portfolio, ranked #425.
Capstone Investment Advisors first reported a position in BSX in Q4 2015 and has held it in 21 quarters since. The position peaked at $9.56M in Q1 2017. 1,665 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Capstone Investment Advisors held 78,247 shares of Boston Scientific worth $4.91M as of Q1 2026.
- Capstone Investment Advisors bought 67,771 Boston Scientific shares in Q1 2026, an estimated $5.42M.
- Boston Scientific made up 0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #425 holding.
- Capstone Investment Advisors first reported a position in Boston Scientific in Q4 2015 and has held it in 21 quarters since.
- Capstone Investment Advisors's Boston Scientific position peaked at $9.56M in Q1 2017.
- 1,665 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.